Clinical trials: Risperidone, completed
Schizophrenia
Efficiency Study to Investigate Blonanserin in Treatment of Schizophrenia When Compared With Risperidone
A Randomized, Double-blinded, Double-dummy, Parallel-controlled and Multicenter Clinical trial to Investigate Blonanserin in Treatment of Schizophrenia when compared with Risperidone
- Trial name
- NCT01516424
- Testing
- Blonanserin, Risperidone
- Where
- 16 sites in China
- Volunteers
- 267 people
- Sponsor
- Marubeni Pharmaceuticals (Suzhou) Co., Ltd.
Schizophrenia
Randomized, Double-blind, Placebo Controlled, Multi-center and Tolerability of RBP-7000 in Schizophrenia Patients
The purpose of this study is to evaluate the efficacy and safety of RBP-7000 compared with placebo in the treatment of patients with schizophrenia.
- Trial name
- NCT02109562
- Testing
- RBP-7000, Risperidone
- Where
- 32 sites in United States
- Volunteers
- 354 people
- Sponsor
- Indivior Inc.
Schizophrenia
Multiple Ascending Dose Study of the Safety, Tolerability, Pharmacokinetic/Efficacy
Evaluate the safety and tolerability of multiple subcutaneous injections of various dosages of risperidone with clinically stable schizophrenia
- Trial name
- NCT01677377
- Testing
- Risperidone, RBP-7000
- Where
- 2 sites in United States
- Volunteers
- 45 people
- Sponsor
- Indivior Inc.
Carcinoma, Non-Small-Cell Lung, Adenocarcinoma
A Study of VAL401 in the Treatment of Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
The objectives of this study are to assess the safety, tolerability, pharmacokinetics and efficacy of VAL401 in the treatment of patients with locally advanced or metastatic non-small cell lung adenocarcinoma.
- Trial name
- NCT02875340
- Testing
- VAL401
- Volunteers
- 8 people
- Sponsor
- ValiSeek Limited
Schizophrenia, Schizophrenia and Disorders With Psychotic Features
Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic Patients
The main objective of the trial is to evaluate, how long an antipsychotic relapse-prevention should be continued and to which time a patient with schizophrenia is protected enough, so that a withdrawal or reduction of the…
- Conditions
- Schizophrenia, Schizophrenia and Disorders With Psychotic Features, Schizoaffective Disorders
- Trial name
- NCT02307396
- Testing
- Olanzapine, Amisulpride, Risperidone
- Where
- Germany
- Volunteers
- 21 people
- Sponsor
- Technical University of Munich
Schizophrenia
Long Term Study of RBP 7000 in the Treatment of Subjects With Schizophrenia
This is a Phase 3, open label study administering RBP-7000 in the treatment of patients with schizophrenia. Study will assess the long-term safety and tolerability of RBP-7000 subcutaneous (SC) injections in subjects with…
- Trial name
- NCT02203838
- Testing
- RBP-7000
- Where
- 48 sites in United States
- Volunteers
- 500 people
- Sponsor
- Indivior Inc.
Autistic Disorder
Biomarkers in Autism of Aripiprazole and Risperidone Treatment (BAART)
The Biomarkers in autism of aripiprazole and risperidone treatment (BAART) project will provide evidence-based guidance in the selection and monitoring of drug treatment of autism.
- Trial name
- BAART (NCT01333072)
- Testing
- Aripiprazole, Risperidone
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Medical University of South Carolina
Schizophrenia, Schizoaffective Disorder
Prospective Cytochrome P450 Genotyping and Clinical Outcomes in Patients With Psychosis
The aim of the study is to examine whether determining treatment strategies based upon Cytochrome P450 2D6 (CYP2D6) genotype will improve drug response rates and clinical outcome in patients with psychosis.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Psychotic Disorder Not Otherwise Specified, Severe Bipolar Disorder With Psychotic Features
- Trial name
- NCT01878513
- Testing
- risperidone
- Where
- United States
- Volunteers
- 88 people
- Sponsor
- Northwell Health
Schizophrenia, Schizoaffective Disorder
Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared To Injectables: Evaluating Efficacy
This study is designed to find out whether taking antipsychotic medication once every two weeks by injection compared to taking daily oral medication will help people with schizophrenia maintain better control of their symptoms.
- Trial name
- PROACTIVE (NCT00330863)
- Testing
- Risperidone microspheres, Risperidone, Olanzapine
- Where
- 8 sites in United States
- Volunteers
- 357 people
- Sponsor
- Northwell Health
Aggression, Attention Deficit-Hyperactivity
Metabolic Effects of Antipsychotics in Children
The project aims to describe and compare the outcome of 12 weeks of prospective, randomized treatment with olanzapine, risperidone or aripiprazole on insulin action in skeletal muscle, liver and adipose tissue, abdominal fat…
- Conditions
- Aggression, Attention Deficit-Hyperactivity, Oppositional Defiant Disorder, Pervasive Development Disorders
- Trial name
- MEAC (NCT00205699)
- Testing
- risperidone, olanzapine, aripiprazole
- Where
- United States
- Volunteers
- 144 people
- Sponsor
- Washington University School of Medicine
Bipolar Disorder
Risperidone Plus Mood Stabilizer in Treatment of Mixed Mania
The study aims to assess the efficacy and tolerability of risperidone added to lithium, valproate or lamotrigine in patients experiencing a manic episode with depressive or irritable features.
- Trial name
- NCT00294255
- Testing
- Risperidone
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Schizophrenia
An Inpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Treatment Of Acute Exacerbation Of Schizophrenia
This study aims to evaluate whether PF-02545920 is safe and effective in the treatment of acute exacerbation of schizophrenia during a 4-week inpatient treatment period.
- Trial name
- NCT01175135
- Testing
- PF-02545920, Risperidone
- Where
- 46 sites in United States, Germany and 1 more
- Volunteers
- 259 people
- Sponsor
- Pfizer
Imaging of the Brain and Antipsychotics, Neuronal Network Changes
Acute D2 Receptor Blockade Induced Neuronal Network Changes in Human Volunteers
To detect the effect of second-generation antipsychotic drug on the neural activity.
- Trial name
- NCT01931059
- Testing
- Risperidone
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Northwell Health
Schizophrenia
Use of Galantamine and CDP-choline (Citicoline) to Treat Adults With Schizophrenia
This study will evaluate the effectiveness of galantamine and CDP-choline in improving symptoms associated with schizophrenia.
- Trial name
- STAR-1 (NCT00509067)
- Testing
- Galantamine, CDP-choline, risperidone, olanzapine, quetiapine, ziprasidone, and/or aripiprazole
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Georgetown University
Schizophrenia, Alcoholism
Risperidone and Desipramine in Alcohol Use and Schizophrenia
Note: In June 2013, the study design was changed from a randomized controlled study of risperidone + despiramine vs. risperidone vs. placebo to an open label pre-post study of risperidone (or risperidone-like drug) + desipramine.
- Conditions
- Schizophrenia, Alcoholism, Dual Diagnosis
- Trial name
- RADIAUS (NCT01411085)
- Testing
- Risperidone + Desipramine
- Where
- 4 sites in United States
- Volunteers
- 12 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Schizophrenia
Cannabidiol as a Different Type of an Antipsychotic: Drug Delivery and Interaction Study
Despite recent advances in the understanding and treatment of schizophrenia, this devastating disease still affects one percent of world's population.
- Trial name
- CBD-IS (NCT02051387)
- Testing
- Cannabidiol CR, Cannabidiol, Amisulpride
- Where
- 2 sites in Germany
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Central Institute of Mental Health, Mannheim
Dissociative Disorders, Schizophrenia
Assessment of Adverse Events in a Naive Pediatric Population Treated With an Antipsychotic
We propose a prospective multicenter study, whose originality lies in the inclusion of the naive child and adolescent population.
- Trial name
- NCT02007928
- Testing
- Rispéridone, aripiprazole, olanzapine
- Where
- 14 sites in France
- Volunteers
- 200 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Psychosis, Schizophrenia
Risperidone LA Heathcare Resource Study
The primary objective of this pilot study is to evaluate the impact of switching 30 subjects from an existing antipsychotic to risperidone long acting on healthcare resource utilization.
- Trial name
- NCT00272597
- Testing
- Risperidone
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- University of British Columbia
Healthy
Bioequivalence Study of Risperidone 1.0 mg Tablets of Torrent Pharmaceuticals Limited., India and Risperdal® (Risperidone) 1.0 mg Tablets of Janssen Pharmaceutical Products, LP, USA, in Healthy Human Adult Subjects, Under Fasting Conditions
Objective: To assess the bioequivalence of Risperidone 1.0 mg tablets of Torrent Pharmaceuticals Limited., India and Risperdal® (Risperidone) 1.0 mg tablets of Janssen Pharmaceutical Products, LP, USA, in healthy human adult…
- Trial name
- NCT00939497
- Testing
- Risperidone
- Where
- India
- Sponsor
- Torrent Pharmaceuticals Limited
Healthy
Bioequivalence Study of Risperidone 1 mg Tablets of Torrent Pharmaceuticals Limited, India and Risperdal® (Risperidone) 1 mg Tablets of Janssen Pharmaceutical Products, LP, USA, in Healthy Human Adult Subjects, Under Fed Conditions
Objective: To assess the bioequivalence of Risperidone 1.0 mg tablets of Torrent Pharmaceuticals Limited., India and Risperdal® (Risperidone) 1.0 mg tablets of Janssen Pharmaceutical Products, LP, USA, in healthy human adult…
- Trial name
- NCT00939926
- Testing
- Risperidone
- Where
- India
- Sponsor
- Torrent Pharmaceuticals Limited